Evaluation of hyperbaric XXXX as a chemosensitizer in the treatment of @entity43 in xenografts in @entity19 .

@entity43 @entity1 @entity851 @entity5 @entity19 @entity2295 @entity26 @entity900
BACKGROUND: Resistance to chemotherapy is common in bulky @entity5 such as @entity43 . Hyperbaric @entity26 (HBO) oxygenates hypoxic tissues and promotes @entity2295 . These unique properties of HBO may help overcome chemotherapy resistance by increasing both @entity5 perfusion and cellular sensitivity. This study was undertaken to determine if HBO increases the response of @entity43 to @entity900 chemotherapy. METHODS: In Phase I, 64 nu/nu @entity19 were divided into four groups and subcutaneously inoculated with cells from the A2780 @entity1 @entity43 cell line. Group 1 served as controls. Group 2 received weekly intraperitoneal @entity900 (3.15 mg/kg). Group 3 was exposed to HBO (dives) at 2.4 atmospheres absolute pressure for 90 minutes, 7 days a week. Group 4 received both @entity900 and HBO. In Phase II, 72 @entity19 were divided into two groups and similarly inoculated. Both groups received weekly intraperitoneal @entity900 (2.5 mg/kg). Group 1 was not exposed to HBO. Group 2 was exposed to HBO for 5 days a week. RESULTS: @entity5 was found in @entity5 of @entity19 exposed to HBO (P = 0.0001). There was significant (P = 0.014) @entity851 in Phase I for @entity19 receiving both @entity900 and HBO compared with those treated with @entity900 alone. This significance was noted after just two doses of @entity900 but subsequently lost due to reduced numbers of @entity19 . In Phase II, @entity2295 was detectable after 10 HBO treatments (2 weeks) and was maximal after 15 treatments (3 weeks). CONCLUSIONS: Hyperbaric @entity26 increases vascularity in @entity5 such as @entity43 . There appears to be a relationship between increased vascularity and enhanced response to chemotherapy that merits further investigation.
